Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease with a poor prognosis and limited 35 treatment options. Many compounds have shown efficacy in pre-clinical models of this condition, 36 but only Pirfenidone and Nintedanib have been approved for clinical use. It is widely accepted that 37 the current animal models of IPF need to be improved and in this review we have critically evaluated 38 the current state of play of preclinical models of IPF and discuss the challenges facing this field. The 39 popular model of a single I.T. administration of bleomycin could be adapted to provide a more 40 progressive fibrosis as is thought to occur in humans. Furthermore, currently the majority of new 41 drugs are investigated in preclinical models of IPF are dosed using a prophylactic dosing regimen, 42
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whereas patients are almost always treated after the fibrosis is well established. Using a therapeutic 43 dosing regimen in preclinical models would be a better way to establish potential efficacy of new 44 drugs. The most popular endpoints examined in pre-clinical models of IPF are histological scoring 45 and lung collagen content. However in IPF patients imaging and lung function tests are more 46 commonly used as end points. We propose that examining more clinically relevant endpoints in pre-47
Introduction 53
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterised by scarring 54 of the lung tissue causing impaired gas exchange leading to symptoms such as dyspnoea, dry cough, 55 and general fatigue. IPF is more prevalent in males than females and risk factors include increased 56 age, a history of smoking and working in environments with poor air quality, such as mining [1] [2] [3] [4] . 57 M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
3 There also appears to be a genetic component of IPF with variations of genes such as MUC5B and 58 TOLLIP conferring a greater risk of developing IPF [3] . 59
Despite the relatively recent approval of Pirfenidone and Nintedanib (approved in Europe in 2011 60 and 2015 respectively) which have both been shown to slow the progression of IPF in clinical trials 61 [5, 6] the prognosis of IPF is still very poor with approximately 50% of patients dying within 2-5 years 62 of diagnosis [1, 2, 4] . Part of the reason for this poor prognosis is that the symptoms of IPF often 63 don't present until the disease is at an advanced stage [2, 7] , and also delays in diagnosis can occur 64 as the symptoms of IPF are shared with several other respiratory disorders, and either a high 65 resolution CT scan or lung biopsy are required to definitively diagnose IPF [8] . The fact that IPF can 66 remain undetected for so long means that pharmacological intervention is often not introduced until 67 the disease is already well established. In addition, the pathogenesis of IPF is not fully understood. 68 However, it is currently thought that repeated lung injury or infection leads to an aberrant wound 69
healing process which causes massive extra cellular matrix deposition and the scarring of lung tissue 70 that is characteristic of IPF [9] . 71
The incomplete understanding of the disease and lack of safe and effective treatment makes IPF a 72 disease with considerable unmet need requiring novel approaches to treatment. To this end there 73 has been a considerable amount of research in this area and a wide variety of different in vivo 74 models have been used to investigate IPF over many years, but there remains no consensus on 75 preclinical tests best used to model IPF and to have predictive value of clinical efficacy. Many 76 different research groups have published work attempting to model IPF use different species, 77 different fibrotic insults and different dosing routes and regimes to illicit a fibrotic response in the 78 lungs of the animals. However, there is little consistency between laboratories regarding optimal 79 protocols for these preclinical models. 80
The aim of this review is therefore to detail and compare the different in vivo models used to 81 investigate IPF, to review the effects of different pharmacological classes of drugs evaluated in these 82 MANUSCRIPT   4   models and to critically discuss how these effects have translated into treatment for patients with  83 IPF. Furthermore, we have suggested potential ways for improving the current preclinical models in 84 IPF research. 85
Overview of current pre-clinical models of pulmonary fibrosis 86
Pulmonary fibrosis like features can be induced in experimental animals by very diverse agents, and 87 these different agents can be administered via many different routes and using distinctive dosing 88 regimens. We have summarised these different approaches in Table 1 . Since the early 1970's when 89 bleomycin was recognised as a drug able to induce pulmonary fibrosis as an unwanted effect in 90 some patients, bleomycin has been the most widely used agent to induce pulmonary fibrosis in 91 animals [10] [11] [12] . Bleomycin induces pulmonary fibrosis by production of DNA-cleaving superoxide 92 and hydroxide free radicals which cause single and double stranded DNA breaks [13] . This damage 93 preferentially occurs in the lungs because of low levels of bleomycin hydrolase, a bleomycin 94 inactivating enzyme [14] . Bleomycin has been used in a variety of different species via a number of 95 administration routes and regimes. Probably the most popular and best characterised animal model 96 involves a single I.T. dose of bleomycin in rats or mice. This dosing regime leads to a neutrophil 97 driven inflammatory response which lasts approximately 7-10 days, which then transforms into a 98 fibrotic response from approximately Day 14 [15, 16] . Terminal investigations are typically carried out 99 on Day 21 or 28 after the initial bleomycin dose. This model has provided valuable insight into the 100 process of pulmonary fibrosis, for example elucidation of the importance of the role of TGF-β in the 101 development of IPF [17] . Furthermore, this model was used in the pre-clinical development of 102
Nintedanib [18] . However, this bleomycin model does have several limitations with the most 103 concerning being the fact that the fibrosis has been shown to spontaneously resolve beyond 28 days 104 [15, 19] . Since fibrosis does not resolve in most patients with pulmonary fibrosis, the use of this 105 model is limited to the evaluation of the efficacy of potential anti-fibrotic compounds 106
prophylactically. Many other bleomycin dose routes and regimes have been used to try and better 107 model the progressive nature of IPF with repeated lower doses of bleomycin delivered both locally
to the lungs [20, 21] or systemically [22, 23] . For example, with a lower repeated I.T. dose of 109 bleomycin, Peng et al [21] were able to show fibrotic like changes in the lungs up to 24 weeks after 110 the initial bleomycin dose. However, the length of time that this model takes to develop and the 111 significant mortality observed with this dosing regimen are limitations of this dosing regimen [21] . 112
As well as bleomycin several other fibrotic agents have been used with varying degrees of success. 113
Fluorescein isothiocyanate (FITC) has been shown to cause fibrosis like changes over a similar time 114 scale to bleomycin. FITC is a fluorescent molecule with the advantage that molecular deposition in 115 the lung can be easily visualised [2, 24, 25] . The disadvantages of this model are that certain 116 histopathological features, such as fibroblast foci, are not observed, and there is a large amount of 117 variation in the fibrotic response generated by different batches of FITC [2] . 118
Administration of silica or asbestos to the lungs has also been shown to illicit persistent fibrosis like 119 changes [18, [26] [27] [28] . However, as with FITC, there are histopathological features that are missing 120 with respect to the histopathological features seen in patients with IPF. The pulmonary conditions 121 that develops following exposure to silica or asbestos are more akin to the human disease of silicosis 122 or asbestosis respectively rather than pulmonary fibrosis. 123
Systemic delivery of paraquat also produces fibrosis like changes in the lungs of animals [29] [30] [31] . 124 However, paraquat is a broad spectrum herbicide that has been shown to cause necrosis in organs 125 other than the lungs (such as kidney and liver) which can cause significant mortality and thus 126 provides considerable challenges as a model associated with fibrosis-specific changes to the lungs 127 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 6 lacks some of the histopathological features seen in patients with IPF such as complex fibroblast foci 133 [1, 2] . 134
Intra-tracheal delivery of transgenes using viral vectors has shown some success, with delivery of 135 genes for factors such as TGF-β1 and IL-1β eliciting fibrotic responses in the lungs of animals [34] [35] [36] . 136
Although delivery of these transgenes leads to a progressive and persistent fibrosis (up to 9 weeks in 137 certain studies [34, 35] , the downside of such models can be that the animals may have an immune 138 response to the viral vector, and the expression of the transgenes is much higher than 139 physiologically possible. Therefore, the pathways through which the transgene products work will be 140 massively over activated which question the relevance of this approach as a model to test potential 141 novel anti-fibrotic compounds. 142
Another animal model of pulmonary fibrosis that has been utilised is a humanized mouse model of 143 IPF, where cells from human patients of IPF are injected into SCID mice. Infusion of human 144 fibroblasts has been shown to lead to increases in fibrosis seen histologically and upregulation of 145 pro-fibrotic genes such as TGF-β1 and surfactant proteins at 63 days post infusion [37] . However, the 146 main issue with this model is the availability of cells from human patients with IPF, and also the 147 length of time to generate fibrosis in this model. 148
As well as many different agents, and dosing regimens, many different species have been used to 149 model IPF. The most common are mice and rats due to the ease of handling, availability of reagents, 150 their well characterised immune systems, and the possibility of utilising transgenic models in mice 151 [38, 39] . There are however, considerable differences in the structure and physiology of rat and 152 mouse lungs compared to human lungs [40] [41] [42] . Furthermore, one particular aspect of human IPF 153 that is impossible to model in rats and mice is cough. Although there is some controversy over 154 whether mice and rats have the ability to cough it is clear that at best they have a greatly reduced 155 sensitivity to common tussive agents such as citric acid or capsaicin that induce cough in patients 156 with IPF [43, 44] . In contrast, guinea pigs have a well characterised and generally robust cough M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 response and so are the animal of choice for studying cough [43, 44] . As chronic cough is a major 158 symptom of IPF affecting over 80% of patients [45, 46] , some groups have used induced pulmonary 159 fibrosis in guinea pigs in order to be able to investigate the cough caused by pulmonary fibrosis. 160
Another feature of rats and mice that may be a limiting factor in their usefulness for the study of 161 pulmonary fibrosis is their small size. Using larger animals to model pulmonary fibrosis can have a 162 number of advantages. For example the use of the sheep [16] has permitted the use of a fibre-optic 163 bronchoscope to deliver bleomycin to a specific segment of lung. This specific delivery of bleomycin 164 means that the overall burden on the animal is much lower as the remaining lung is easily able to 165 compensate for the damage in the segment administered the bleomycin. Due to this compensation 166 of the rest of the lung a higher relative dose of bleomycin can be used in the target segment to 167 induce a more severe fibrosis that may be more akin to what is seen in advanced pulmonary fibrosis 168 patients, a feature of the clinical disease that is difficult to model in animals where the whole lung is 169 exposed to the fibrotic agent leading to significant levels of tissue damage raising a large number of 170 animal welfare issues. 171 A wide variety of different compounds with different mechanisms of action have shown efficacy in 176 animal models of pulmonary fibrosis (see Table 2 ). However, currently only 2 compounds have been 177 approved for the treatment of IPF in humans. In addition to the choice of animal model another 178 variable that is introduced when investigating novel potential anti fibrotic compounds in animal 179 models of pulmonary fibrosis is the dosing regimen used for the drug. Generally, the administration 180 of compounds falls into the categories of either prophylactic or therapeutic administration. Dosing 181 of compounds that are tested prophylactically commences before or on the same day that the 182 fibrosis is first induced. In contrast when drugs are tested therapeutically, this typically begins once 183 the fibrosis is established (for example in the single IT bleomycin model, day 10-14 is often used as 184 the start day for therapeutic dosing with a test compound). 185
Compounds such as prednisolone or melatonin which are anti-inflammatory and anti-oxidant 186 compounds respectively, and other compounds having similar mechanisms of action have shown 187 some efficacy in pre-clinical models when dosed prophylactically [23, 30, 58, 62 ,65 ,66] Unfortunately this study concluded that the minor treatment related change in forced vital capacity 193 (FVC) in patients receiving this combination therapy suggested that marginal clinical benefit, but 194 potentially increased unwanted effects compared with treating with Pirfenidone alone [70]. 195 Another distinct class of compound that has shown promise pre-clinically are anti-coagulants [49, 71, 196 72 It can be seen from the above discussion that the current preclinical models are a poor predictor of 217 clinical efficacy. This may be due to deficiencies in the design of both pre-clinical and clinical studies, 218 but here we focus only on improvements that could be made to the design of pre-clinical studies in 219
IPF. 220
The majority of the compounds tested pre-clinically for the treatment of IPF are tested in models 221 where a single fibrotic insult is used. In humans the development of IPF is thought to be progressive 222 
